ALK Actualización en terapias dirigidas en CPNM ALK+

21 / 48

ALK TKI Status Indication
Ceritinib FDA/EMA Approved Naïve (2016)
After crizo (2014)
Alectinib FDA/EMA Approved Naïve (2017)
After crizo (2015)
Brigatinib FDA Approved After crizo (2017)
Ensartinib Investigational
Lorlatinib FDA Breakthrough
Therapy Designation
After crizo (2018)
TPX-0005 Investigational
Next Generation ALK inhibitors
2nd gen
3rd gen